We are live on ! Find out more
CODX

Co-Diagnostics
CODX

Fund managers haven’t disclosed any holdings of CODX yet.

CODX Hedge Fund Activity: Q1 2026 in Review

14 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2026, worth a combined $91.5K — down 90% from $940K a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CODX and 4 opened new positions — a net loss of 14 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was UBS Group, adding an estimated $21.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $123K sold.

  • 14 institutional investors held Co-Diagnostics (CODX) as of Q1 2026, down from 30 in Q4 2025.
  • Funds reported $91.5K of Co-Diagnostics stock for Q1 2026, down 90% quarter-over-quarter.
  • 4 funds opened new Co-Diagnostics positions in Q1 2026 and 18 closed out, a net change of -14 holders.
  • The largest Co-Diagnostics buyer in Q1 2026 was UBS Group, an estimated $21.6K added.
  • The largest Co-Diagnostics seller in Q1 2026 was Renaissance Technologies, an estimated $123K sold.

Based on aggregated 13F filings for Q1 2026.